NASH
MIRNA

Metabolic Interventions to Resolve NASH with Fibrosis (MIRNA)

Investigator: Eyob Feyssa, MD

The purpose of this study is to evaluate the drug DGAT2i compared to DGAT2i with ACCi on the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Learn more about the MIRNA trial. 

View on ClinicalTrials.gov, MountSinai.gov, and Pfizer.com, or call the Clinical Trials Office at 484-628-8585 for more information.

Primary Sclerosing Cholangitis
PRIMIS

Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults with Primary Sclerosing Cholangitis (PRIMIS)

Investigator: Eyob Feyssa, MD

The purpose of this study is to evaluate whether cilofexor (CILO, previously known as GS-9674) reduces the risk of fibrosis progression among non-cirrhotic subjects with Primary Sclerosing (PSC).

Learn more about the PRIMIS trial.

View on ClinicalTrials.gov and PCSTrial.com, or call the Clinical Trials Office at 484-628-8585 for more information.